Table 2.
Neuroendocrine breast carcinomas compared to the prospective set of ductal carcinomas
| NEBC (n = 39) | Ductal carcinomas (n = 506) | p-value | |
|---|---|---|---|
| Median age at diagnosis | 66.0 | 57.0 | <0.0005 |
| T class | 0.40 | ||
| T1 | 28 (71.8%) | 322 (63.6%) | |
| T2 | 9 (23.1%) | 167 (33.0%) | |
| T3 | 2 (5.1%) | 12 (2.4%) | |
| T4 | 0 (0.0%) | 5 (1.0%) | |
| N class | 0.72 | ||
| N0 | 23 (59.0%) | 314 (62.1%) | |
| N1 | 10 (25.6%) | 149 (29.4%) | |
| N2 | 5 (12.8%) | 41 (8.1%) | |
| N3 | 0 (0.0%) | 2 (0.4%) | |
| Missing | 1 (2.6%) | 0 (0.0%) | |
| HER2 expression | 0.046 | ||
| Negative | 37 (94.9%) | 437 (86.4%) | |
| Positive | 1 (2.6%) | 69 (13.6%) | |
| Missing | 1 (2.6%) | 0 (0.0%) | |
| Estrogen receptor expression | 0.0062 | ||
| Negative | 1 (2.6%) | 103 (20.4%) | |
| Low | 0 (0.0%) | 18 (3.6%) | |
| Moderate | 0 (0.0%) | 25 (4.9%) | |
| High | 37 (94.9%) | 360 (71.1%) | |
| Missing | 1 (2.6%) | 0 (0.0%) | |
| Progesterone receptor expression | 0.088 | ||
| Negative | 4 (10.3%) | 148 (29.2%) | |
| Low | 4 (10.3%) | 61 (12.1%) | |
| Moderate | 5 (12.8%) | 57 (11.3%) | |
| High | 25 (61.5%) | 240 (47.4%) | |
| Missing | 2 (5.1%) | 0 (0.0%) | |
| Ki-67 | 0.060 | ||
| Negative | 0 (0.0%) | 32 (6.3%) | |
| Low | 14 (35.9%) | 217 (43.1%) | |
| Moderate | 15 (38.5%) | 116 (23.0%) | |
| High | 8 (20.5%) | 139 (27.6%) | |
| Missing | 2 (5.1%) | 2 (0.4%) | |
| Adjuvant radiotherapy | 0.23 | ||
| No | 8 (20.5%) | 66 (13.4%) | |
| Yes | 31 (79.5%) | 427 (86.6%) | |
| Adjuvant chemotherapy | 0.00070 | ||
| No | 27 (69.2%) | 207 (40.2%) | |
| Yes | 12 (30.8%) | 299 (59.1%) | |
| Adjuvant endocrine therapy | 0.015 | ||
| No | 7 (17.9%) | 191 (37.7%) | |
| Yes | 32 (82.1%) | 315 (62.3%) |
Legend 2. Prognostic factors and adjuvant treatments of neuroendocrine breast carcinomas (NEBC) compared to the prospective set of ductal carcinomas. Primary metastasized cancers have been excluded. Missing values have not been included to the analysis